{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-233623","form_type":"8-K","ticker":"BURU","cik":"0001814215","company_name":"Nuburu, Inc.","filed_at":"2025-10-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.558799+00:00","generated_at":"2026-05-17T04:28:45.803290+00:00","sec_items":["1.01","5.02","3.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Nuburu to acquire Orbit from Executive Chairman for $12.5M; appoints Co-CEOs, faces audit committee non-compliance","bullets":["Binding LOI to acquire 100% of Orbit S.r.l. from Executive Chairman Zamboni for $12.5M (includes $5M investment and $8.75M in preferred shares subject to stockholder approval).","Co-CEOs appointed: Zamboni (retains Executive Chairman) and Dario Barisoni; each gets $440k salary, 100% target bonus, 1.774M RSUs vesting Oct 31, 2025.","Audit Committee lost second independent director due to Barisoni's appointment; company must regain NYSE American compliance by next annual meeting or one year.","Exclusive 36-month right for Nuburu to market/distribute Orbit's operational resilience platform to global defense sector.","Acquisition includes $3.75M advance payment (offsetting $1.35M credit plus $2.4M cash in four tranches); expected close by Dec 31, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-233623","json":"https://secwatch.observer/filing/0001193125-25-233623.json","markdown":"https://secwatch.observer/filing/0001193125-25-233623.md","text":"https://secwatch.observer/filing/0001193125-25-233623.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1814215/000119312525233623/0001193125-25-233623-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1814215/000119312525233623/buru-20251001.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T04:28:45.803290+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a2399745486ea98e8a4452c72dc02b714fd0e788","claim":"Nuburu, Inc. received a nyse_american noncompliance notice notice regarding audit committee (rules 303A.12(b)).","evidence_excerpt":"October 7, 2025, as required by Section 303A.12(b) of the NYSE Listed Company Manual, the Company submitted an interim written affirmation to the NYSE American Market (the “Exchange”) as a notice of non-compliance with Section 803B(2)(c) of the NYSE American Company Guide (the “Company Guide”), since the Audit Committee is no longer comprised of at least two independent directors. Pursuant to Section 803B(6)(b) of the Company Guide, the Company has until the earlier of its next annual meeting of stockholders or one year from the occurrence of the event that caused the failure to comply with th","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1814215/000119312525233623/0001193125-25-233623-index.htm","confidence":0.9}],"comparable_filings":[{"accession":"0001731122-26-000653","ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2026-05-01T23:59:59+00:00","headline":"Lunai Bioworks completes merger to acquire CNS patent portfolio; issues $20M Series B Preferred Stock","event_type":"m_and_a","sec_items":["1.01","2.01","9.01","3.01","3.02","3.03","5.03"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 1.01, 3.01, 9.01","same event type: m_and_a","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001731122-26-000653","json":"https://secwatch.observer/filing/0001731122-26-000653.json","markdown":"https://secwatch.observer/filing/0001731122-26-000653.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1527728/000173112226000653/0001731122-26-000653-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1527728/000173112226000653/e7595_8k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"October 7, 2025, as required by Section 303A.12(b) of the NYSE Listed Company Manual, the Company submitted an interim written affirmation to the NYSE American Market (the “Exchange”) as a notice of non-compliance with Section 803B(2)(c) of the NYSE American Company Guide (the “Company Guide”), since the Audit Committee is no longer comprised of at least two independent directors. Pursuant to Section 803B(6)(b) of the Company Guide, the Company has until the earlier of its next annual meeting of stockholders or one year from the occurrence of the event that caused the failure to comply with th","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1814215/000119312525233623/0001193125-25-233623-index.htm","comparable_excerpt":"April 20, 2026, the Company received notice from\nthe Panel (in the “Decision”) that it had until April 27, 2026, to regain compliance with the $2.5 million equity requirement\nunder Nasdaq Listing Rule 5550(b)(1)\n (the “S","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112226000653/0001731122-26-000653-index.htm"}},{"accession":"0001193125-26-202554","ticker":"STKL","company_name":"SunOpta Inc.","filed_at":"2026-05-04T23:59:59+00:00","headline":"SunOpta completes acquisition by Refresco affiliate for $6.50/share, going private","event_type":"m_and_a","sec_items":["1.02","2.01","3.01","3.03","5.01","5.02","7.01","9.01"],"materiality_score":1.0,"calibrated_materiality_score":1.0,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 5.02, 9.01","same event type: m_and_a"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-202554","json":"https://secwatch.observer/filing/0001193125-26-202554.json","markdown":"https://secwatch.observer/filing/0001193125-26-202554.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/351834/000119312526202554/0001193125-26-202554-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/351834/000119312526202554/d365148d8k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"October 7, 2025, as required by Section 303A.12(b) of the NYSE Listed Company Manual, the Company submitted an interim written affirmation to the NYSE American Market (the “Exchange”) as a notice of non-compliance with Section 803B(2)(c) of the NYSE American Company Guide (the “Company Guide”), since the Audit Committee is no longer comprised of at least two independent directors. Pursuant to Section 803B(6)(b) of the Company Guide, the Company has until the earlier of its next annual meeting of stockholders or one year from the occurrence of the event that caused the failure to comply with th","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1814215/000119312525233623/0001193125-25-233623-index.htm","comparable_excerpt":"May 1, 2026, the Company notified the Nasdaq Stock Market LLC (“Nasdaq”) of the consummation of the Arrangement on May 1, 2026 and requested that Nasdaq halt trading of the Common Shares effective as of 5:00 p.m., Easter","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/351834/000119312526202554/0001193125-26-202554-index.htm"}},{"accession":"0001062993-26-002900","ticker":"MDCX","company_name":"Medicus Pharma Ltd.","filed_at":"2026-05-27T20:45:00+00:00","headline":"Medicus Pharma closes $22M secured notes with Streeterville; receives Nasdaq MVLS non-compliance notice","event_type":"debt","sec_items":["1.01","2.03","3.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 1.01, 3.01, 9.01","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001062993-26-002900","json":"https://secwatch.observer/filing/0001062993-26-002900.json","markdown":"https://secwatch.observer/filing/0001062993-26-002900.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1997296/000106299326002900/0001062993-26-002900-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1997296/000106299326002900/form8k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"October 7, 2025, as required by Section 303A.12(b) of the NYSE Listed Company Manual, the Company submitted an interim written affirmation to the NYSE American Market (the “Exchange”) as a notice of non-compliance with Section 803B(2)(c) of the NYSE American Company Guide (the “Company Guide”), since the Audit Committee is no longer comprised of at least two independent directors. Pursuant to Section 803B(6)(b) of the Company Guide, the Company has until the earlier of its next annual meeting of stockholders or one year from the occurrence of the event that caused the failure to comply with th","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1814215/000119312525233623/0001193125-25-233623-index.htm","comparable_excerpt":"May 20, 2026, the Company received written notice (the \"Notice\") from the Listing Qualifications Department of the Nasdaq notifying the Company that it is not in compliance with the minimum Market Value of Listed Securit","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1997296/000106299326002900/0001062993-26-002900-index.htm"}},{"accession":"0001493152-26-025244","ticker":"XHLD","company_name":"TEN Holdings, Inc.","filed_at":"2026-05-26T20:05:22+00:00","headline":"TEN Holdings receives Nasdaq equity deficiency notice; issues 500k shares for $500k","event_type":"regulatory","sec_items":["1.01","3.01","3.02","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 1.01, 3.01, 9.01","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-025244","json":"https://secwatch.observer/filing/0001493152-26-025244.json","markdown":"https://secwatch.observer/filing/0001493152-26-025244.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2030954/000149315226025244/0001493152-26-025244-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2030954/000149315226025244/form8-k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"October 7, 2025, as required by Section 303A.12(b) of the NYSE Listed Company Manual, the Company submitted an interim written affirmation to the NYSE American Market (the “Exchange”) as a notice of non-compliance with Section 803B(2)(c) of the NYSE American Company Guide (the “Company Guide”), since the Audit Committee is no longer comprised of at least two independent directors. Pursuant to Section 803B(6)(b) of the Company Guide, the Company has until the earlier of its next annual meeting of stockholders or one year from the occurrence of the event that caused the failure to comply with th","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1814215/000119312525233623/0001193125-25-233623-index.htm","comparable_excerpt":"May 26, 2026, the Company received a deficiency letter from the Listing Qualifications Department (the “ Staff ”)\nof The Nasdaq Stock Market LLC (“ Nasdaq ”), notifying the Company that it is not in compliance with Nasda","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2030954/000149315226025244/0001493152-26-025244-index.htm"}},{"accession":"0001193125-26-226691","ticker":"RANI","company_name":"Rani Therapeutics Holdings, Inc.","filed_at":"2026-05-15T20:08:23+00:00","headline":"Rani Therapeutics Q1 net loss narrows to $8M; Nasdaq bid price non-compliance; CFO to depart","event_type":"earnings","sec_items":["2.02","3.01","5.02","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 5.02, 9.01","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-226691","json":"https://secwatch.observer/filing/0001193125-26-226691.json","markdown":"https://secwatch.observer/filing/0001193125-26-226691.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1856725/000119312526226691/0001193125-26-226691-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1856725/000119312526226691/rani-20260511.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"October 7, 2025, as required by Section 303A.12(b) of the NYSE Listed Company Manual, the Company submitted an interim written affirmation to the NYSE American Market (the “Exchange”) as a notice of non-compliance with Section 803B(2)(c) of the NYSE American Company Guide (the “Company Guide”), since the Audit Committee is no longer comprised of at least two independent directors. Pursuant to Section 803B(6)(b) of the Company Guide, the Company has until the earlier of its next annual meeting of stockholders or one year from the occurrence of the event that caused the failure to comply with th","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1814215/000119312525233623/0001193125-25-233623-index.htm","comparable_excerpt":"May 11, 2026, the Company received a letter from the Nasdaq Stock Exchange LLC (“Nasdaq”), notifying the Company that, based on the closing bid price of the Company’s Class A common stock, par value $0.0001 per share (th","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1856725/000119312526226691/0001193125-26-226691-index.htm"}},{"accession":"0001213900-26-055912","ticker":"ISPC","company_name":"iSpecimen Inc.","filed_at":"2026-05-13T21:00:25+00:00","headline":"iSpecimen prices $2.5M private placement at $5.12/share; regains Nasdaq minimum bid price compliance","event_type":"other_material","sec_items":["1.01","3.01","3.02","7.01","8.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 1.01, 3.01, 9.01","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-055912","json":"https://secwatch.observer/filing/0001213900-26-055912.json","markdown":"https://secwatch.observer/filing/0001213900-26-055912.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1558569/000121390026055912/0001213900-26-055912-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1558569/000121390026055912/ea0290143-8k_ispecimen.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"October 7, 2025, as required by Section 303A.12(b) of the NYSE Listed Company Manual, the Company submitted an interim written affirmation to the NYSE American Market (the “Exchange”) as a notice of non-compliance with Section 803B(2)(c) of the NYSE American Company Guide (the “Company Guide”), since the Audit Committee is no longer comprised of at least two independent directors. Pursuant to Section 803B(6)(b) of the Company Guide, the Company has until the earlier of its next annual meeting of stockholders or one year from the occurrence of the event that caused the failure to comply with th","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1814215/000119312525233623/0001193125-25-233623-index.htm","comparable_excerpt":"minimum $1.00 per share required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Minimum\nBid Price Requirement”) for the prior 30 consecutive business days. On May 12, 2026","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1558569/000121390026055912/0001213900-26-055912-index.htm"}},{"accession":"0001829126-26-004960","ticker":"PMI","company_name":"Picard Medical, Inc.","filed_at":"2026-05-11T21:08:14+00:00","headline":"Picard Medical raises $5M in public offering, receives NYSE American delisting notice for low equity","event_type":"other_material","sec_items":["1.01","3.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 1.01, 3.01, 9.01","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001829126-26-004960","json":"https://secwatch.observer/filing/0001829126-26-004960.json","markdown":"https://secwatch.observer/filing/0001829126-26-004960.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2030617/000182912626004960/0001829126-26-004960-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2030617/000182912626004960/picardmedical_8k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"October 7, 2025, as required by Section 303A.12(b) of the NYSE Listed Company Manual, the Company submitted an interim written affirmation to the NYSE American Market (the “Exchange”) as a notice of non-compliance with Section 803B(2)(c) of the NYSE American Company Guide (the “Company Guide”), since the Audit Committee is no longer comprised of at least two independent directors. Pursuant to Section 803B(6)(b) of the Company Guide, the Company has until the earlier of its next annual meeting of stockholders or one year from the occurrence of the event that caused the failure to comply with th","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1814215/000119312525233623/0001193125-25-233623-index.htm","comparable_excerpt":"May 8, 2026, the Company received a written notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) indicating that the Company is not in compliance with the NYSE American continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company Guide (the “Company Guide”) requiring a company to have stockholders’ equity of at least $4.0 million if it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. The Notice states that the Company reported a stockholders’ equity of approximately $3.8 million as of","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2030617/000182912626004960/0001829126-26-004960-index.htm"}},{"accession":"0001731122-26-000668","ticker":"SBEV","company_name":"SPLASH BEVERAGE GROUP, INC.","filed_at":"2026-05-05T23:59:59+00:00","headline":"Splash Beverage receives NYSE delisting notice; shareholders' equity negative $15.3M","event_type":"regulatory","sec_items":["1.01","1.02","3.01","3.02","5.03","7.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 1.01, 3.01, 9.01","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001731122-26-000668","json":"https://secwatch.observer/filing/0001731122-26-000668.json","markdown":"https://secwatch.observer/filing/0001731122-26-000668.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1553788/000173112226000668/0001731122-26-000668-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1553788/000173112226000668/e7604_8-k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"October 7, 2025, as required by Section 303A.12(b) of the NYSE Listed Company Manual, the Company submitted an interim written affirmation to the NYSE American Market (the “Exchange”) as a notice of non-compliance with Section 803B(2)(c) of the NYSE American Company Guide (the “Company Guide”), since the Audit Committee is no longer comprised of at least two independent directors. Pursuant to Section 803B(6)(b) of the Company Guide, the Company has until the earlier of its next annual meeting of stockholders or one year from the occurrence of the event that caused the failure to comply with th","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1814215/000119312525233623/0001193125-25-233623-index.htm","comparable_excerpt":"April 29, 2026, the Company received notice from NYSE Regulation (the “NYSE”)\nthat the Company is not in compliance with the shareholders’ equity requirement of $6 million as of December 31, 2025 as outlined\nin Section 1","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1553788/000173112226000668/0001731122-26-000668-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}